NASDAQ:RNA Avidity Biosciences (RNA) Stock Price, News & Analysis $8.95 -0.61 (-6.38%) As of 09/18/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Avidity Biosciences Stock (NASDAQ:RNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Avidity Biosciences alerts:Sign Up Key Stats Today's Range$8.66▼$9.6750-Day Range$8.95▼$14.6052-Week Range$8.66▼$16.77Volume1.04 million shsAverage Volume307,747 shsMarket Capitalization$153.13 millionP/E RatioN/ADividend YieldN/APrice Target$63.75Consensus RatingHold Company Overview Avidity Biosciences, Inc. is a biopharmaceutical company focused on developing RNA therapeutics for diseases that have historically been difficult to treat with conventional drug-delivery methods. Founded in 2012 and headquartered in San Diego, California, the company develops medicines intended to address genetic disorders, with an emphasis on diseases affecting muscles. Avidity’s proprietary Antibody Oligonucleotide Conjugate (AOC) platform combines the targeting capabilities of monoclonal antibodies with the gene-modifying potential of oligonucleotides, including small interfering RNA and antisense oligonucleotides. The approach is designed to help deliver RNA-based medicines into specific tissues and cells, where they can influence the production or processing of disease-related proteins. The company’s pipeline includes delpacibart etedesiran, also known as del-desiran or AOC 1001, an investigational therapy for myotonic dystrophy type 1. Other clinical and preclinical programs have targeted conditions such as facioscapulohumeral muscular dystrophy and Duchenne muscular dystrophy. Avidity conducts research and clinical development activities through collaborations and studies involving patients and medical institutions in multiple regions. Sarah Boyce serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Avidity Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreRNA MarketRank™: Avidity Biosciences scored higher than 34% of companies evaluated by MarketBeat, and ranked 703rd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingAvidity Biosciences has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 strong buy rating, 3 buy ratings, 11 hold ratings, and 1 sell rating.Upside PotentialAvidity Biosciences has a consensus price target of $63.75, representing about 612.3% upside from its current price of $8.95.Amount of Analyst CoverageAvidity Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Avidity Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Avidity Biosciences are expected to decrease in the coming year, from ($5.08) to ($8.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avidity Biosciences is -4.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avidity Biosciences is -4.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Avidity Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.37% of the float of Avidity Biosciences has been sold short.Short Interest Ratio / Days to CoverAvidity Biosciences has a short interest ratio ("days to cover") of 19.79, which indicates bearish sentiment.Change versus previous monthShort interest in Avidity Biosciences has recently decreased by 3.72%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvidity Biosciences does not currently pay a dividend.Dividend GrowthAvidity Biosciences does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.07 News SentimentAvidity Biosciences has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Avidity Biosciences this week, compared to 4 articles on an average week.Search Interest2 people have searched for RNA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Avidity Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders3.83% of the stock of Avidity Biosciences is held by insiders.Percentage Held by InstitutionsAvidity Biosciences has minimal institutional ownership at this time.Read more about Avidity Biosciences' insider trading history. Receive RNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RNA Stock News HeadlinesNovartis RNA drug falls short in rare muscle disease studySeptember 9, 2026 | finance.yahoo.comAtrium Therapeutics to Participate in Upcoming Investor ConferencesSeptember 2, 2026 | prnewswire.comYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type of finance to build lasting wealth. Legendary investor Joel Greenblatt calls it 'the closest thing to a perpetual motion machine you will ever see.' One investor famously turned 50000 dollars into 900 million using this approach. Porter Stansberry breaks down its origins and mechanics in a new free documentary. | Porter & Company (Ad)Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 20, 2026 | prnewswire.comAtrium Therapeutics Reports Second Quarter 2026 Financial ResultsAugust 13, 2026 | prnewswire.comAtrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular CollaborationAugust 13, 2026 | prnewswire.comAtrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)July 20, 2026 | prnewswire.comAtrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 SyndromeJuly 14, 2026 | prnewswire.comSee More Headlines RNA Stock Analysis - Frequently Asked Questions How have RNA shares performed this year? Avidity Biosciences' stock was trading at $72.13 at the start of the year. Since then, RNA stock has decreased by 87.6% and is now trading at $8.95. How were Avidity Biosciences' earnings last quarter? Avidity Biosciences, Inc. (NASDAQ:RNA) issued its quarterly earnings results on Thursday, August, 13th. The biotechnology company reported ($1.18) earnings per share for the quarter, beating analysts' consensus estimates of ($1.42) by $0.24. The biotechnology company had revenue of $3 million for the quarter, compared to analysts' expectations of $0.67 million. When did Avidity Biosciences IPO? Avidity Biosciences (RNA) raised $216 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 14,400,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO. How do I buy shares of Avidity Biosciences? Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Avidity Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avidity Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Eli Lilly and Company (LLY), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings8/13/2026Today9/20/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RNA CIK1599901 Webwww.aviditybiosciences.com Phone858-401-7900FaxN/AEmployees190Year Founded2013Price Target and Rating Average Price Target for Avidity Biosciences$63.75 High Price Target$74.00 Low Price Target$25.00 Potential Upside/Downside+612.3%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio8.73 Quick Ratio8.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares17,110,000Free Float16,451,000Market Cap$153.13 million OptionableOptionable BetaN/A Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:RNA) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | Sponsored“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
